沙格列汀联合苯溴马隆对糖尿病患者合并高尿酸血症的疗效分析

Efficacy analysis of saxagliptin combined with benzbromarone in diabetic patients with hyperuricemia

摘要:

目的 探究沙格列汀联合苯溴马隆治疗糖尿病合并高尿酸血症患者的临床效果。方法 采用前瞻性的研究方法，选取2018年2月—2022年10月中国人民解放军联勤保障部队第九〇四医院常州医疗区收治的82例糖尿病合并高尿酸血症患者，依照随机数字表法分为对照组与观察组，每组41例。对照组给予沙格列汀治疗，观察组给予沙格列汀联合苯溴马隆治疗，两组均连续治疗12周。比较两组患者血糖［空腹血糖（FBG）、餐后2 h血糖（2 hPG）、糖化血红蛋白（HbA1c）］、空腹胰岛素（FINS）、血尿酸（UA）、血肌酐（Scr）、尿素氮（BUN）、血脂［总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）］，以及临床疗效和不良反应。结果 观察组治疗前后FBG、2 hPG、HbA1c、FINS、UA、Scr、BUN的差值均高于对照组（P <0.05）。观察组治疗前后TC、TG、LDL-C的差值均高于对照组（P <0.05）。观察组临床疗效总有效率高于对照组（P <0.05）。观察组与对照组不良反应总发生率比较，差异无统计学意义（P >0.05）。结论 沙格列汀联合苯溴马隆治疗糖尿病合并高尿酸血症患者可有效降低血糖、FINS、UA、Scr、BUN及血脂，提高临床疗效，且安全可靠。

Abstract:

Objective To investigate the clinical efficacy of saxagliptin combined with benzbromarone in diabetic patients with hyperuricemia.Methods A prospective study was conducted on 82 diabetic patients with hyperuricemia admitted to our hospital between February 2018 and October 2022. Patients were randomly divided into a control group (n = 41, saxagliptin alone) and an observation group (n = 41, saxagliptin + benzbromarone). Both groups were treated for 12 weeks. Changes in blood glucose [fasting blood glucose (FBG), 2-hour postprandial blood g1ucose (2 hPG), hemoglobin A1c (HbA1c) ], fasting insulin (FINS), uric acid (UA), serum creatinine (Scr), blood urea nitrogen (BUN), and blood lipids [total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) ] were compared, along with clinical efficacy and adverse reactions.Results The magnitude of change (pre- vs. post-treatment) in FBG, 2hPG, HbA1c, FINS, UA, Scr, and BUN was significantly greater in the observation group than in the control group (P < 0.05). The magnitude of change in TC, TG, and LDL-C was also significantly greater in the observation group (P < 0.05). The total clinical efficacy rate was significantly higher in the observation group than in the control group (P < 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P > 0.05).Conclusion Saxagliptin combined with benzbromarone effectively reduces blood glucose, insulin, UA, Scr, BUN, and lipid levels in diabetic patients with hyperuricemia, improving clinical efficacy with a favorable safety profile.